LUVOX (fluvoxamine maleate) by ANI Pharmaceuticals is neurons. First approved in 2007.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
LUVOX (fluvoxamine maleate) is an oral selective serotonin reuptake inhibitor (SSRI) approved for treating obsessive-compulsive disorder and other psychiatric conditions. It works by inhibiting the reuptake of serotonin in neurons, increasing serotonin availability in the brain. The drug has been marketed since 2007 and is now a mature, well-established therapeutic option.
As LOE approaches, LUVOX brand team faces shrinking revenue; focus shifts from growth to defensive market positioning and generic transition planning.
neurons. Fluvoxamine has been shown to be a potent inhibitor of the serotonin reuptake transporter in preclinical studies, both in vitro and in vivo .
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers
Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects
A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects
A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers
Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.
Worked on LUVOX at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on LUVOX offers limited career growth due to LOE approaching and zero linked job openings in current data. Career advancement will depend on company's portfolio breadth and your ability to transition to next-generation mental health products or leadership roles in lifecycle management.